Fasching, P. A., Brucker, C., Decker, T., Engel, A., Göhler, T., Jackisch, C., . . . Wöckel, A. (2026). Real-world progression-free survival and overall survival in patients with HR+/HER2− advanced breast cancer treated in first-line with ribociclib, endocrine monotherapy or chemotherapy: Results from the observational RIBANNA study : cancer therapy and prevention. International journal of cancer. https://doi.org/10.1002/ijc.70397
Chicago Style (17th ed.) CitationFasching, Peter Andreas, et al. "Real-world Progression-free Survival and Overall Survival in Patients with HR+/HER2− Advanced Breast Cancer Treated in First-line with Ribociclib, Endocrine Monotherapy or Chemotherapy: Results from the Observational RIBANNA Study : Cancer Therapy and Prevention." International Journal of Cancer 2026. https://doi.org/10.1002/ijc.70397.
MLA (9th ed.) CitationFasching, Peter Andreas, et al. "Real-world Progression-free Survival and Overall Survival in Patients with HR+/HER2− Advanced Breast Cancer Treated in First-line with Ribociclib, Endocrine Monotherapy or Chemotherapy: Results from the Observational RIBANNA Study : Cancer Therapy and Prevention." International Journal of Cancer, 2026, https://doi.org/10.1002/ijc.70397.